FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced, as part of the ongoing integration of CV Therapeutics, changes to the company’s cardiovascular research and development organization leadership. Louis G. Lange, MD, PhD has decided to assume a part-time position at Gilead and will therefore be transitioning from his role as Executive Vice President, Cardiovascular Therapeutics.
